Human metapneumovirus (HMPV) is a respiratory virus that causes illness ranging from a common cold to serious pneumonia, and it has been circulating in humans for well over a century despite only being formally identified in 2001. It ranks alongside respiratory syncytial virus (RSV) and influenza as a leading cause of acute respiratory infections worldwide, yet most people have never heard of it.1PubMed Central. Human metapneumovirus (hMPV): the virus who came with the common cold Almost every child on earth has been infected by age five, and the virus keeps coming back throughout life because immunity to it is frustratingly incomplete.
A Virus Hiding in Plain Sight
Dutch researchers first isolated HMPV in 2001 from children with unexplained respiratory illness, but the virus was not new. Retrospective testing of stored blood samples showed it had been infecting people for at least half a century before anyone gave it a name.2PubMed Central. Zoonotic Origins of Human Metapneumovirus: A Journey from Birds to Humans Evolutionary analyses estimate the sampled genetic diversity of HMPV arose roughly 120 to 130 years ago, and the virus likely jumped from birds to humans around 200 years ago. HMPV’s closest relative in the animal kingdom is avian metapneumovirus subgroup C (AMPV-C), a pathogen of poultry and wild birds, which strongly suggests the human virus emerged after a zoonotic crossover event.3Microbiology Society (Journal of General Virology). Evolutionary dynamics of human and avian metapneumoviruses
The reason it went undetected for so long is partly practical: HMPV is notoriously difficult to grow in the lab. The virus needs an external enzyme called trypsin to activate its fusion protein before it can replicate in cell cultures, and it grows slowly even under ideal conditions.4PubMed Central. Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH Before molecular testing became routine, countless HMPV infections were simply logged as “unknown respiratory virus” or attributed to something else entirely.
How HMPV Gets Into Your Cells
HMPV is an enveloped RNA virus, meaning it has a fatty outer coat studded with surface proteins. The most important of these is the fusion (F) protein, which does double duty: it latches onto cells in the airway and then punches through the cell membrane to deliver the viral genetic material inside. Most related viruses need a separate attachment protein to land on cells first, but HMPV’s F protein handles both steps on its own.5PubMed Central. Breaking in: human metapneumovirus fusion and entry This self-sufficiency of the F protein is shared with RSV and is one reason those two viruses are grouped together. It also makes the F protein a prime target for vaccines and antibody therapies, since blocking it effectively prevents the virus from entering cells at all.
When and Where Outbreaks Happen
In temperate climates, HMPV circulates mostly during late winter and spring, overlapping with the tail end of flu season. Tropical regions see year-round activity with less predictable seasonal spikes.6PubMed Central. Human Metapneumovirus: A Comprehensive Epidemiological Analysis of a Global Respiratory Threat The timing varies from year to year even within the same city. A study tracking pediatric infections in southeastern China over several years found that the peak typically fell in December or January, but in one year it shifted all the way to May. Temperature and rainfall were both linked to the timing: colder and drier conditions generally meant more infections.7PubMed Central. Seasonal distribution and epidemiological characteristics of human metapneumovirus infections in pediatric inpatients in Southeast China
A separate ten-year study in southern China detected HMPV in about 3.5% of children tested, with the spring months seeing the highest rates. Children under one year old made up the largest share of positive cases.8PubMed. Epidemiology, genetic characteristics, and association with meteorological factors of human metapneumovirus infection in children in southern China: A 10-year retrospective study That percentage may sound modest, but spread across an entire population of young children, it translates to a huge number of infections every year. The COVID-19 pandemic disrupted normal patterns temporarily; many places saw a suppression of HMPV during lockdown periods followed by rebound surges once restrictions lifted.
Symptoms and Who Is Most at Risk
For most healthy adults, HMPV looks and feels like a bad cold: cough, runny nose, sore throat, sometimes a low fever. The illness resolves on its own in a week or two. The trouble starts at the extremes of age and in people with weakened immune systems. In young children, HMPV commonly causes bronchiolitis, the same swelling of small airways that RSV is known for. Hospitalized children typically present with fever, cough, wheezing, fast breathing, and chest retractions.9PubMed Central. Metapneumovirus and its place in childhood
In older adults and immunocompromised patients, the clinical picture can turn serious. A systematic review found that HMPV accounted for roughly 4% of symptomatic respiratory infections in older adults during a given year, climbing to about 5% in high-risk adults during the respiratory season. Among high-risk adults who sought medical care, about half required hospitalization. Of those hospitalized, around 7% ended up in intensive care, and roughly 9% died.10PubMed Central. The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review Those mortality figures are comparable to what is seen with influenza in similar populations, which is striking given how little public attention HMPV receives.11PubMed. Emerging threat of Human Metapneumovirus (HMPV) and strategies for its containment and control
HMPV Versus RSV in Children
Because HMPV and RSV cause nearly identical symptoms in young children, clinicians cannot reliably tell them apart without a lab test. Studies comparing the two have found that illness severity is broadly similar: children hospitalized with HMPV and those hospitalized with RSV had the same average length of stay and comparable rates of needing supplemental oxygen or mechanical ventilation.12PubMed Central. Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity There are some differences in the fine print, though. HMPV tends to hit slightly older children; one large comparison found the median age for HMPV-associated lower respiratory infections was about 2.5 years versus 1.6 years for RSV. Children with HMPV also ran higher fevers for longer and showed higher levels of inflammatory markers in their blood. On the other hand, RSV was more likely to cause visible respiratory distress with chest retractions.13PubMed Central. Comparison of human metapneumovirus and respiratory syncytial virus in children with acute lower respiratory infections in Wenzhou, China from 2021 to 2022: a retrospective study
One uncomfortable finding from the earlier comparison: children with HMPV were significantly more likely to be admitted to the ICU than those with RSV (about 38% versus 12%), and they received antibiotics at much higher rates. That antibiotic use probably reflects diagnostic uncertainty more than a genuine need, since HMPV is a virus and does not respond to antibiotics. When clinicians do not immediately identify the pathogen, they often treat empirically for a possible bacterial infection, especially if the child looks sick.14PubMed Central. Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity
Why You Keep Getting Reinfected
Nearly every child worldwide has antibodies to HMPV by age five, yet reinfections happen throughout life.15PubMed Central. Human Metapneumovirus Reinfection in Aged Mice Recapitulates Increased Disease Severity in Elderly Humans Infected with Human Metapneumovirus A Japanese study tracking healthy adults over five years found that virtually all of them already had HMPV antibodies at the start, yet about 17% showed serological evidence of reinfection during the follow-up period. The antibody levels that most adults carry — enough to test positive, but not enough to block the virus — appear insufficient for protection. After a reinfection event, antibody levels spiked but drifted back down to baseline within two to three years.16PubMed. Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults
This waning and incomplete immunity is one of the biggest challenges for vaccine developers. Unlike measles, where a single good immune response confers lifelong protection, HMPV behaves more like RSV: the body’s immune memory is partial, and the virus exploits that gap.17PubMed Central. Humoral immunity to human metapneumovirus infection in adults The silver lining is that repeat infections in healthy adults are usually milder than the first encounter, which typically happens in early childhood. The real danger of reinfection emerges in older adults, where immune aging compounds the problem and subsequent infections can be just as severe as the first.
Genetic Groups and Why They Matter
HMPV comes in two major genetic groups, A and B, each of which splits further into subgroups (A1, A2a, A2b, B1, B2). Despite those labels, the groups are remarkably similar at the protein level. An analysis of the fusion gene over a twenty-year span found that the predicted amino acid sequences across all groups shared about 96% identity, and there was minimal progressive drift over time. The estimated mutation rate was quite slow — roughly seven mutations per 10,000 genetic positions per year — and the lineages remained stable across two decades.18PubMed Central. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years Surveillance studies confirm that multiple lineages circulate simultaneously and the dominant one shifts from season to season. In Turkey over two consecutive epidemic seasons, B2 and A2b swapped places as the most common lineage, and the A1 group appeared only in one of the two years.19Mikrobiyoloji Bulteni. Phylogenetic variability of human metapneumovirus strains circulating in Turkey during two consecutive epidemic seasons
The good news for vaccine design is that HMPV’s slow evolution means the key surface proteins are not a fast-moving target, unlike influenza. A vaccine built around the F protein could potentially cover all circulating lineages because the protein’s functional shape is so tightly constrained that it cannot change much without breaking itself.
How HMPV Is Diagnosed
Because HMPV symptoms overlap so heavily with RSV, influenza, and other respiratory viruses, laboratory testing is the only way to confirm a diagnosis. The standard approach today is PCR-based testing, which detects the virus’s genetic material in a nose or throat swab. PCR methods offer better accuracy, faster results, and fewer safety concerns for lab staff compared to older techniques like growing the virus in cell culture.20PubMed Central. Advances in laboratory assays for detecting human metapneumovirus Many hospitals now use multiplex panels that check for a dozen or more respiratory pathogens in a single test run, and HMPV is routinely included on these panels.21PubMed Central. Development of a multiplex one step RT-PCR that detects eighteen respiratory viruses in clinical specimens and comparison with real time RT-PCR
That said, testing practices vary enormously by hospital and region. In many clinical settings, a patient who looks like they have a cold or flu is simply sent home without ever being swabbed. HMPV testing is more common in hospitalized patients, in pediatric wards, and when a respiratory panel is ordered for other reasons. This inconsistent testing is a major reason HMPV’s true burden is probably underestimated.
Treatment Options Are Thin
There is no approved antiviral drug specifically targeting HMPV, and no licensed vaccine yet exists. Treatment remains supportive: fluids, oxygen if needed, fever control, and monitoring. For most healthy children and adults, that is all that is required.22PubMed. An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities
In severe cases among immunocompromised patients — people who have received organ transplants, for instance, or who are undergoing chemotherapy — clinicians have occasionally used ribavirin (an antiviral sometimes given for RSV) along with intravenous immunoglobulin (IVIG), which provides a broad dose of antibodies. Case reports have described successful outcomes with this combination, but no large trials have been conducted to confirm it works consistently.23PubMed Central. The human metapneumovirus: a case series and review of the literature Without rigorous trial data, this remains a last-resort approach rather than standard care.
The Complication of Coinfections
HMPV does not always act alone. Because it damages the airway lining, it can open the door for bacteria to establish a foothold. Case reports have documented previously healthy adults developing severe illness when HMPV infection was complicated by a bacterial coinfection. In one case, a person with asthma contracted HMPV alongside group A streptococcus and progressed to acute respiratory distress syndrome and shock.24PubMed Central. Severe Human Metapneumovirus and Group A Streptococcus Pneumonia in an Immunocompetent Adult Another report described HMPV-related heart inflammation complicated by a simultaneous Klebsiella pneumoniae infection, with a rapid and fatal deterioration despite aggressive treatment.25American Journal of Case Reports. Metapneumovirus-Induced Myocarditis Complicated by Klebsiella pneumoniae Co-Infection: A Case Report These are individual cases, not common scenarios, but they illustrate that HMPV can occasionally set the stage for dangerous secondary infections, particularly in people with underlying conditions.
Vaccines and Monoclonal Antibodies on the Horizon
The success of new RSV vaccines and monoclonal antibodies (like nirsevimab for infants) has accelerated interest in doing the same for HMPV. Several approaches are in development. One combination vaccine, IVX-A12, uses computationally designed virus-like particles to generate immune responses against both RSV and HMPV in a single shot. In a Phase II trial in adults aged 60 to 85, the vaccine was well tolerated: side effects were mostly mild to moderate, and it boosted neutralizing antibodies against both HMPV A and B subgroups by two- to threefold. Most of those antibody increases persisted above baseline for at least a year.26PubMed. A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age Whether that antibody boost translates into fewer infections and hospitalizations will need larger trials to answer.
On the monoclonal antibody front, researchers have isolated several potent antibodies from the blood of naturally infected adults that can block HMPV across all subgroups. In animal models, these antibodies reduced viral levels in the lungs by ten- to twentyfold when given before infection.27Immunity. Human memory B cell responses to the human metapneumovirus fusion glycoprotein One particularly powerful antibody, called MPV467, showed effectiveness at extremely low concentrations and worked not only when given before infection but also when administered 72 hours after the virus had already taken hold.28PubMed Central. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus Another candidate, 4F11, binds the F protein in an unusual one-to-one configuration and significantly cut viral loads in hamster lungs and nasal passages.29PubMed Central. Development of a potent monoclonal antibody for treatment of human metapneumovirus infections All of these remain in preclinical or early clinical stages, but the pipeline is busier than it has ever been.
Links to Childhood Asthma
Beyond the acute illness, there are hints that early HMPV infection may leave a mark on lung health. A study following children from infancy found that those who had HMPV-related bronchiolitis as babies were significantly more likely to have asthma by age five. In multivariate analysis, HMPV bronchiolitis was the strongest risk factor for preschool-age asthma, with an odds ratio higher than that of RSV bronchiolitis or allergic rhinitis.30PubMed. Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5 This does not prove that HMPV causes asthma — it could be that children already prone to reactive airways are also prone to severe viral infections — but the association is strong enough to have drawn interest from pulmonologists studying wheezing disorders in children.
Preventing Spread
HMPV spreads the same way most respiratory viruses do: through respiratory droplets from coughing and sneezing, close personal contact, and touching contaminated surfaces. Because it is an enveloped virus, its fatty outer coat is easily disrupted by soap, alcohol-based hand sanitizers, and standard surface disinfectants. A striking example of how infection control works came from a psychiatric hospital that experienced repeated HMPV outbreaks among patients who were unable to maintain hand hygiene on their own. When staff began delivering alcohol hand rub directly to patients four times a day, the number of people involved in nosocomial respiratory virus outbreaks plummeted from 60 in one year to six the next.31PubMed. Outbreak of human metapneumovirus infection in psychiatric inpatients: implications for directly observed use of alcohol hand rub in prevention of nosocomial outbreaks Basic measures — handwashing, staying home when sick, covering coughs — remain the main line of defense until vaccines or antivirals become available.
The Cost of a Virus Nobody Talks About
HMPV’s relative obscurity does not mean it is cheap to manage. A U.S. study of hospitalized children found wide year-to-year variation in HMPV-related admissions, ranging from 9 to 79 per 100,000 children depending on the season. Children under two were hit hardest, at about 200 hospitalizations per 100,000. Among those hospitalized, 18% required intensive care and 6% needed mechanical ventilation. The median hospital cost per patient was over $5,500, with significantly higher bills for children who had chronic medical conditions.32PubMed Central. Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children
In Spain, a retrospective analysis of HMPV hospitalizations between 2016 and 2023 found that total hospital costs exceeded €22 million over that period, averaging about €2.8 million per year, with a clear upward trend over time.33Infectious Diseases and Therapy. Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016–2023): A Retrospective Study Part of that increase likely reflects better testing — as more hospitals add HMPV to multiplex respiratory panels, more cases get counted. But rising awareness of the pathogen has not yet translated into the kind of public-health investment that influenza and RSV receive. HMPV remains, in the words of researchers who study it, the major respiratory virus that got the least attention.